ReviewFrontiers in genetics2014
Potential of epigenetic therapies in non-cancerous conditions.
Review in Frontiers in genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Differential DNA methylation associated with delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a systematic review.Neurosurgical review · 2024Pooled it
- DNA methylation in chronic kidney disease.BMC nephrology · 2025Review
- Identification of Sjögren's syndrome patient subgroups by clustering of labial salivary gland DNA methylation profiles.PloS one · 2023Article
- Dihydroartemisinin suppresses renal fibrosis in mice by inhibiting DNA-methyltransferase 1 and increasing Klotho.Acta pharmacologica Sinica · 2022Article
- Effects of metabolic memory on inflammation and fibrosis associated with diabetic kidney disease: an epigenetic perspective.Clinical epigenetics · 2021Review
- Hypomethylation mediates genetic association with the major histocompatibility complex genes in Sjögren's syndrome.PloS one · 2021Article
- Preclinical and Clinical Epigenetic-Based Reconsideration of Beckwith-Wiedemann Syndrome.Frontiers in genetics · 2020Review
- Whole-genome bisulfite sequencing in systemic sclerosis provides novel targets to understand disease pathogenesis.BMC medical genomics · 2019Article
- A high-fat diet alters genome-wide DNA methylation and gene expression in SM/J mice.BMC genomics · 2018Article
- Immune senescence, epigenetics and autoimmunity.Clinical immunology (Orlando, Fla.) · 2018Review
- Epigenetics and Metabolism in Health and Disease.Frontiers in genetics · 2018Article
- Epigenetics in SLE.Current rheumatology reports · 2017Review
- Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.Seminars in liver disease · 2017Article
- MicroRNAs in idiopathic pulmonary fibrosis: involvement in pathogenesis and potential use in diagnosis and therapeutics.Acta pharmaceutica Sinica. B · 2016Review
- Epigenetics and Primary Biliary Cirrhosis: a Comprehensive Review and Implications for Autoimmunity.Clinical reviews in allergy & immunology · 2016Review
- Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics.Annals of the New York Academy of Sciences · 2015Review
- Endothelial epigenetics in biomechanical stress: disturbed flow-mediated epigenomic plasticity in vivo and in vitro.Arteriosclerosis, thrombosis, and vascular biology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
There has been an explosion of knowledge in the epigenetics field in the past 20 years. The first epigenetic therapies have arrived in the clinic for cancer treatments. In contrast, much of the promise of epigenetic therapies for non-cancerous conditions remains in the laboratories. The current review will focus on the recent progress that has been made in understanding the pathogenic role of epigenetics in immune and inflammatory conditions, and how the knowledge may provide much needed new therapeutic targets for many autoimmune diseases. Dietary factors are increasingly recognized as potential modifiers of epigenetic marks that can influence health and diseases across generations. The current epigenomics revolution will almost certainly complement the explosion of personal genetics medicine to help guide treatment decisions and disease risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.